138 related articles for article (PubMed ID: 38218577)
1. The enigmatic mode of action of the lantibiotic epilancin 15X.
Wang X; Xu Y; Martin NI; Breukink E
Biochim Biophys Acta Biomembr; 2024 Mar; 1866(3):184282. PubMed ID: 38218577
[TBL] [Abstract][Full Text] [Related]
2. Investigation into the mechanism of action of the antimicrobial peptide epilancin 15X.
Wu C; Lower BA; Moreira R; Dorantes D; Le T; Giurgiu C; Shi Y; van der Donk WA
Front Microbiol; 2023; 14():1247222. PubMed ID: 38029153
[TBL] [Abstract][Full Text] [Related]
3. Chemical synthesis and biological activity of analogues of the lantibiotic epilancin 15X.
Knerr PJ; van der Donk WA
J Am Chem Soc; 2012 May; 134(18):7648-51. PubMed ID: 22524291
[TBL] [Abstract][Full Text] [Related]
4. Isolation and structural characterization of epilancin 15X, a novel lantibiotic from a clinical strain of Staphylococcus epidermidis.
Ekkelenkamp MB; Hanssen M; Danny Hsu ST; de Jong A; Milatovic D; Verhoef J; van Nuland NA
FEBS Lett; 2005 Mar; 579(9):1917-22. PubMed ID: 15792796
[TBL] [Abstract][Full Text] [Related]
5. Biosynthesis of the antimicrobial peptide epilancin 15X and its N-terminal lactate.
Velásquez JE; Zhang X; van der Donk WA
Chem Biol; 2011 Jul; 18(7):857-67. PubMed ID: 21802007
[TBL] [Abstract][Full Text] [Related]
6. Sequence analysis by NMR spectroscopy of the peptide lantibiotic epilancin K7 from Staphylococcus epidermidis K7.
van de Kamp M; Horstink LM; van den Hooven HW; Konings RN; Hilbers CW; Frey A; Sahl HG; Metzger JW; van de Ven FJ
Eur J Biochem; 1995 Feb; 227(3):757-71. PubMed ID: 7867636
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the primary structure of the lantibiotic epilancin K7 from Staphylococcus epidermidis K7. Cloning and characterisation of the epilancin-K7-encoding gene and NMR analysis of mature epilancin K7.
van de Kamp M; van den Hooven HW; Konings RN; Bierbaum G; Sahl HG; Kuipers OP; Siezen RJ; de Vos WM; Hilbers CW; van de Ven FJ
Eur J Biochem; 1995 Jun; 230(2):587-600. PubMed ID: 7607233
[TBL] [Abstract][Full Text] [Related]
8. Analyzing mechanisms of action of antimicrobial peptides on bacterial membranes requires multiple complimentary assays and different bacterial strains.
Wang X; van Beekveld RAM; Xu Y; Parmar A; Das S; Singh I; Breukink E
Biochim Biophys Acta Biomembr; 2023 Aug; 1865(6):184160. PubMed ID: 37100361
[TBL] [Abstract][Full Text] [Related]
9. The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II.
Wiedemann I; Böttiger T; Bonelli RR; Wiese A; Hagge SO; Gutsmann T; Seydel U; Deegan L; Hill C; Ross P; Sahl HG
Mol Microbiol; 2006 Jul; 61(2):285-96. PubMed ID: 16771847
[TBL] [Abstract][Full Text] [Related]
10. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics.
Brötz H; Josten M; Wiedemann I; Schneider U; Götz F; Bierbaum G; Sahl HG
Mol Microbiol; 1998 Oct; 30(2):317-27. PubMed ID: 9791177
[TBL] [Abstract][Full Text] [Related]
11. Staphylococcus epidermidis bacteriocin A37 kills natural competitors with a unique mechanism of action.
Puls JS; Winnerling B; Power JJ; Krüger AM; Brajtenbach D; Johnson M; Bilici K; Camus L; Fließwasser T; Schneider T; Sahl HG; Ghosal D; Kubitscheck U; Heilbronner S; Grein F
ISME J; 2024 Jan; 18(1):. PubMed ID: 38470311
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of pore formation and membrane disruption by the antimicrobial lantibiotic peptide Mutacin 1140.
Pokhrel R; Bhattarai N; Baral P; Gerstman BS; Park JH; Handfield M; Chapagain PP
Phys Chem Chem Phys; 2019 Jun; 21(23):12530-12539. PubMed ID: 31147666
[TBL] [Abstract][Full Text] [Related]
13. The lantibiotic mersacidin is a strong inducer of the cell wall stress response of Staphylococcus aureus.
Sass P; Jansen A; Szekat C; Sass V; Sahl HG; Bierbaum G
BMC Microbiol; 2008 Oct; 8():186. PubMed ID: 18947397
[TBL] [Abstract][Full Text] [Related]
14. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.
Hasper HE; Kramer NE; Smith JL; Hillman JD; Zachariah C; Kuipers OP; de Kruijff B; Breukink E
Science; 2006 Sep; 313(5793):1636-7. PubMed ID: 16973881
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of nukacin ISK-1: an alternative mode of action.
Roy U; Islam MR; Nagao J; Iida H; Mahin AA; Li M; Zendo T; Nakayama J; Sonomoto K
Biosci Biotechnol Biochem; 2014; 78(7):1270-3. PubMed ID: 25229869
[TBL] [Abstract][Full Text] [Related]
16. Dual mode of action of amylolysin: a type-B lantibiotic produced by Bacillus amyloliquefaciens GA1.
Arguelles Arias A; Joris B; Fickers P
Protein Pept Lett; 2014 Apr; 21(4):336-40. PubMed ID: 24164268
[TBL] [Abstract][Full Text] [Related]
17. Lipid II-based antimicrobial activity of the lantibiotic plantaricin C.
Wiedemann I; Böttiger T; Bonelli RR; Schneider T; Sahl HG; Martínez B
Appl Environ Microbiol; 2006 Apr; 72(4):2809-14. PubMed ID: 16597986
[TBL] [Abstract][Full Text] [Related]
18. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies.
Bonelli RR; Schneider T; Sahl HG; Wiedemann I
Antimicrob Agents Chemother; 2006 Apr; 50(4):1449-57. PubMed ID: 16569864
[TBL] [Abstract][Full Text] [Related]
19. Effects of the lantibiotic mersacidin on the morphology of staphylococci.
Molitor E; Kluczny C; Brötz H; Bierbaum G; Jack R; Sahl HG
Zentralbl Bakteriol; 1996 Jul; 284(2-3):318-28. PubMed ID: 8837393
[TBL] [Abstract][Full Text] [Related]
20. Posttranslationally modified bacteriocins--the lantibiotics.
Guder A; Wiedemann I; Sahl HG
Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
